Please assess the completion status of the following clinical trial:

Trial Title: Perimenopausal Estrogen Replacement Therapy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* must be between 45 and 60 years of age~* must be in the menopause transition (irregular/ absent menstrual cycles or hot flashes)~* must be are medically healthy~Exclusion Criteria:~- currently taking antidepressant medication

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo patches for 12 months and placebo pills for 12 days every 2 months.
- Estradiol (Type: EXPERIMENTAL): Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.

Based on this trial design, predict the completion outcome and termination type (if applicable).